Advice
following a full submission:
avatrombopag (Doptelet®) is accepted for use within NHSScotland.
Indication under review: treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.
In two phase III studies in patients with severe thrombocytopenia with chronic liver disease who were scheduled to undergo an invasive procedure, avatrombopag was superior to placebo for the proportion of patients who did not require a platelet transfusion or any rescue procedure for bleeding after randomisation and up to 7 days following the procedure.
Medicine details
- Medicine name:
- avatrombopag (Doptelet)
- SMC ID:
- SMC2296
- Indication:
For the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.
- Pharmaceutical company
- Swedish Orphan
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 December 2020